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AbsTrACT
background and objective systemic sclerosis (ssc) is 
a severe autoimmune disease, in which the pathogenesis 
is dependent on both genetic and epigenetic factors. 
altered gene expression in ssc monocytes, particularly 
of interferon (iFn)-responsive genes, suggests their 
involvement in ssc development. We investigated the 
correlation between epigenetic histone marks and gene 
expression in ssc monocytes.
Methods chromatin immunoprecipitation followed by 
sequencing (chiPseq) for histone marks H3K4me3 and 
H3K27ac was performed on monocytes of nine healthy 
controls and 14 patients with ssc. rna sequencing was 
performed in parallel to identify aberrantly expressed 
genes and their correlation with the levels of H3K4me3 
and H3K27ac located nearby their transcription start 
sites. chiP-qPcr assays were used to verify the role of 
bromodomain proteins, H3K27ac and sTaTs on iFn-
responsive gene expression.
results 1046 and 534 genomic loci showed aberrant 
H3K4me3 and H3K27ac marks, respectively, in ssc 
monocytes. The expression of 381 genes was directly and 
significantly proportional to the levels of such chromatin 
marks present near their transcription start site. Genes 
correlated to altered histone marks were enriched for 
immune, iFn and antiviral pathways and presented with 
recurrent binding sites for irF and sTaT transcription 
factors at their promoters. iFnα induced the binding 
of sTaT1 and sTaT2 at the promoter of two of these 
genes, while blocking acetylation readers using the 
bromodomain BeT family inhibitor JQ1 suppressed their 
expression.
Conclusion ssc monocytes have altered chromatin 
marks correlating with their iFn signature. enzymes 
modulating these reversible marks may provide 
interesting therapeutic targets to restore monocyte 
homeostasis to treat or even prevent ssc.
InTroduCTIon
Systemic sclerosis (SSc) is a severe autoimmune 
disease characterised by progressive and uncontrol-
lable fibrosis of the skin and visceral organs including 
the lungs, heart and kidneys causing morbidity and 
increased mortality.1 The aetiology of SSc is poorly 
understood and no preventive measures or curing 
therapy exists. Research on the onset and progression 
Key messages
What is already known about this subject?
 ► Monocytes isolated from patients with 
systemic sclerosis (SSc) present with an altered 
transcriptome profile, particularly in interferon 
(IFN)-responsive genes, however the underlying 
pathways responsible of these aberrances are 
unclear.
 ► Chromatin remodelling driven by histone 
modifications entails an important epigenetic 
factor regulating gene expression. Previous 
studies in SSc have only looked at single 
promoter or total changes of histone 
modifications.
What does this study add?
 ► Simultaneous analysis of genome-wide histone 
alterations and transcriptomics data in SSc 
identified that altered H3K4me3 and H3K27ac, 
epigenetically imprinting the activation of 
promoters and enhancers, are associated with 
aberrant gene expression in SSc monocytes.
 ► Alterations in histone acetylation and 
methylation are mostly associated to IFN-
related genes and are similar in all SSc subsets, 
including patients with early SSc, suggesting 
that these aberrant epigenetic marks may 
contribute to disease onset by initiating or 
sustaining this pathway.
How might this impact on clinical practice or 
future developments?
 ► Enzymes responsible for the deposition 
and maintenance of histone acetylation or 
methylation, or their binding partners, may 
provide interesting therapeutic targets to 
restore monocyte homeostasis to treat or even 
prevent SSc.
 on 6 M









is: first published as 10.1136/annrheum





2 van der Kroef M, et al. Ann Rheum Dis 2019;0:1–10. doi:10.1136/annrheumdis-2018-214295
Autoimmunity
Table 1 Demographics and clinical characteristics of patients included in the study
discovery cohort qPCr/ChIP-qPCr validation cohort
RNAseq/qPCR HC ncssc lcssc dcssc HC eassc ncssc lcssc dcssc
ChIPseq/ChIP-qPCR HC lcssc dcssc HC eassc ncssc lcssc dcssc
n 9 6 11 7 19 13 27 22 17
7 9 6 5 4 4 3 3
Age (years) 53 (45–64) 43 (34–55) 58 (51–67) 63 (43–69) 50 (43–55) 74 (43–78) 59 (50–68) 63 (52–71) 49 (44–61)
53 (39–64) 58 (53–68) 64 (41–70) 44 (38–50) 54 (27–79) 55 (40–59) 76 (65–77) 46 (36–50)
Female, n (%) 5 (56) 5 (83) 8 (72) 3 (43) 17 (89) 13 (100) 27 (100) 21 (95) 13 (76)
4 (57) 6 (67) 2 (33) 5 (100) 4 (100) 4 (100) 3 (100) 3 (100)
ANA, n pos (%) – 6 (100) 10 (91) 7 (100) – 13 (100) 26 (96) 21 (95) 16 (94)
– 8 (89) 6 (100) – 4 (100) 4 (100) 3 (100) 3 (100)
ACA, n pos (%) – 3 (50) 6 (55) 1 (14) – 11 (59) 20 (74) 12 (55) 0 (0)
– 5 (56) 1 (17) – 4 (100) 3 (75) 3 (100) 0 (0.0)
Scl70, n pos (%) – 2 (33) 2 (18) 4 (57) – 1 (18) 1 (4) 8 (36) 10 (59)
– 1 (11) 3 (50) – 0 (0.0) 0 (0.0) 0 (0.0) 3 (100)
mRSS – 0 7 (2–9) 11 (7–18) – 0 0 4 (3–5) 9 (5–14)
– 7 (2–9) 11 (7–18) – 0 0 4 (2–8) 6 (2–26)
ILD, n (%) – 1 (17) 2 (18) 5 (71) – 0 2 (7) 6 (27) 12 (71)
– 2 (22) 4 (67) – 0 0 (15) 0 (29) 3 (100)
Disease duration – 3 (2–5) 10 (2–17) 8 (2–16) – – 8 (3–17) 21 (8–26) 8 (2–16)
– 4 (2–15) 9 (2–19) – – 7 (2–15) 17 (11–23) 13 (2–18)
Values reported indicate the number (n) of patients and the median for each parameter (IQR), if not otherwise indicated. Blue and White fields indicate features of patients of the 
same cohort analysed either with RNAseq/qPCR or ChIPseq/ChIP-qPCR, respectively.
ACA, anticentromere antibodies; ANA, antinuclear antibodies; HC, healthy controls; ILD, interstitial lung disease; Scl70, antitopoisomerase antibodies; dcSSc, diffuse cutaneous 
SSc; eaSSc, early SSc; lcSSc, limited cutaneous SSc; mRSS, modified Rodnan skin score; ncSSc, non-cutaneous SSc; pos, positivity.
of this deforming disease points at an early activation of circulating 
immune cells and their subsequent infiltration into the affected 
organs.2–5 The release of cytokines and chemokines by these cells 
can cause activation of endothelial cells and fibroblasts, resulting 
in deposition of excessive amounts of extracellular matrix.6–9 Later 
stages of SSc are often marked by irreversible skin fibrosis affecting 
the reticular dermis and subjacent adipose layer resulting in a 
largely acellular and atrophic skin.10 The mechanisms triggering 
this fibrotic response are still poorly understood. Preventing the 
activation and migration of immune cells could have beneficial 
effects on the disease prognosis or halt fibrosis onset.
Monocyte numbers are higher in patients with SSc in both the 
skin and circulation.5 Furthermore, SSc monocytes present with an 
increased expression of interferon (IFN)-dependent genes,11 12 an 
enhanced profibrotic phenotype13 and release larger amounts of 
proinflammatory mediators upon stimulation.14 Importantly, the 
expression of IFN-responsive genes in circulating immune cells 
and in the skin of patients with SSc correlates with the degree of 
skin fibrosis and the presence of severe clinical phenotypes.15–18 
Although the differences between healthy and SSc monocytes are 
well established, the underlying pathways causing their aberrant 
gene expression and activated phenotype as well as their impor-
tance in the onset of fibrosis and perpetuation of SSc are unknown. 
Unravelling these pathways could lead to the identification of 
novel therapeutic targets.
Genome-wide association studies (GWAS) have demonstrated 
that SSc susceptibility loci are linked to immune-related genes, 
indicating that immune system dysregulation is likely a driving 
force of SSc development.19 20 However, considering the low 
concordance rate of SSc in monozygotic twins (4.2%)21 it is clear 
that genetic factors account for a small percentage of the risk to 
develop SSc. Environmental influences altering epigenetic factors 
such as histone modifications, non-coding RNA and DNA methyl-
ation are thought to play a major role in SSc development.20
Histones are fundamental proteins that stabilise and store 
DNA in chromatin form. Post-transcriptional modifications 
of histones lead to structural changes of the chromatin, either 
allowing or repressing gene transcription. Trimethylation of 
lysine 4 of histone 3 (H3K4me3) indicates active promoters 
while acetylation on lysine 27 of histone 3 (H3K27ac) is found 
in active enhancer and promoter elements.22 23 Histone modifi-
cations in fibroblasts and B cells of patients with SSc have been 
implicated in their altered phenotype.20 However, the impor-
tance of epigenetic mechanisms underlying immune system 
dysregulation in SSc and their role in the development of fibrosis 
are unknown for most immune cell subsets including monocytes.
With the aim of investigating the potential for epigenetic 
targeting in SSc, we examined the association of altered histone 
modifications at gene promoters and enhancers with differential 
gene expression in SSc monocytes, using ChIPseq of H3K4me3 
and H3K27ac in parallel with transcriptome analysis.
MeTHods And MATerIAls
study participants
Peripheral blood was drawn from patients with SSc as well as age 
and gender-matched healthy control (HC). Informed consent was 
obtained from all patients and healthy donors enrolled in the study 
at the University Medical Center Utrecht, the Maasstad Medical 
Center Rotterdam and the IRCCS Policlinico of Milan. All samples 
and clinical information were treated anonymously right after 
they were obtained. All patients with SSc fulfilled the American 
College of Rheumatology/European League Against Rheumatism 
(ACR/EULAR) 2013 classification criteria and were divided into a 
discovery and a validation cohort (table 1). All individuals in the 
discovery cohort were of European ancestry (self-reported and 
confirmed by principal component analysis (PCA) of genotyping 
data (not shown)). The discovery cohort was analysed by RNAseq, 
while ChIPseq experiments were conducted on a subset of patients 
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of the same cohort, according to sample availability. Patients 
with SSc were subdivided into limited cutaneous SSc (lcSSc) and 
diffuse cutaneous SSc (dcSSc) subsets on the basis of the extent 
of skin fibrosis (Leroy, J Rheumatol, 1988). Patients with non-cu-
taneous SSc met the 2013 ACR/EULAR criteria of SSc without 
having fibrosis at the time of recruitment. Patients with early SSc 
(eaSSc) presented with Raynaud’s phenomenon in combination 
with either typical nailfold videocapillaroscopy abnormalities or 
SSc-specific autoantibodies. Ongoing treatment regimen of the 
discovery cohort is reflected in the online supplementary table S4.
A detailed description of the methods and materials used for 
experiments can be found in the online supplementary data.
resulTs
The transcriptome profile and distribution of the histone 
marks H3K4me3 and H3K27ac are altered in monocytes of 
patients with ssc
Consistent with previous literature based on microarray analysis,24 
RNAseq of monocytes from lcSSc (n=11), dcSSc (n=7) and HC 
(n=9) (table 1) demonstrated that the transcriptome of SSc mono-
cytes is markedly different from that of their healthy counterparts 
(online supplementary figure S1A). Upregulated genes were partic-
ularly enriched in pathways relevant for monocyte activation and 
pathways associated with SSc such as IFN response, cytokine/
chemokine signalling and intracellular immune activation path-
ways (online supplementary figure S1B). PCA revealed no strong 
transcriptomic differences between treated and treatment naïve 
patients (not shown).
To gain insights into factors underlying alterations in the tran-
scriptome profile, genome-wide screening of the level of H3K4me3 
and H3K27ac histone modifications was performed using ChIPseq 
analysis on a subset of subjects from the same cohort (lcSSc, n=9; 
dcSSc, n=6; HC, n=7) (table 1). Out of 13 860 H3K4me3 and 13 
364 H3K27ac peaks identified and localised within 20 kbp from 
the transcription start site (TSS) of a gene, 1046 and 534, respec-
tively, were differentially abundant in at least one group of patients 
with SSc compared with HC (figure 1A). 55.6% of the H3K4me3 
and 61.1% of the H3K27ac peaks were upregulated in patients 
with SSc.
Significant changes in the levels of H3K4me3 and H3K27ac 
mainly occurred in genomic regions containing promoters and 
promoter-flanking regions (figure 1B), indicating that altered 
histone marks in patients with SSc may affect the expression 
of neighbouring genes. To assess this hypothesis, variations in 
H3K4me3 and H3K27ac were paralleled with expression changes 
of genes in proximity of the peaks. Consistent with previous litera-
ture demonstrating the presence of these marks at active promoters 
and enhancers,25 increased levels of H3K4me3 and H3K27ac were 
significantly associated with the upregulation of nearby genes, 
while a decrease in these marks correlated with downregulated 
gene expression (figure 1C). These findings demonstrated that SSc 
monocytes carry alterations of the chromatin landscape in regions 
relevant for gene transcription that are associated with changes in 
gene expression
Variations in H3K4me3 and H3K27ac are associated with the 
increased expression of immune, IFn and antiviral response-
related genes
To identify genes whose expression is most strongly influenced 
by altered histone marks in SSc monocytes, the abundance of 
H3K4me3 and H3K27ac was directly correlated with the mRNA 
level of nearby genes. The expression of 302 and 114 genes was 
directly and significantly proportional to the amount of H3K4me3 
and H3K27ac near their TSS, respectively (figure 2A). For 35 genes, 
the expression was significantly correlated with both chromatin 
marks (figure 2A). Pathway enrichment analysis revealed that genes 
whose expression is correlated with increased histone marks are 
involved in immune regulatory processes identified as dysregulated 
by means of RNAseq, including IFN and antiviral-related pathways 
and signalling implicated in cell-to-cell communication (figure 2B). 
Genes correlating with decreased H3K4me3 or H3K27ac marks 
were not enriched in any pathways. Demonstrating the reproduc-
ibility of these findings, the association between the expression of 
two IFN-responsive genes (figure 2C), myxoma resistance protein 
1 (MX1) and cytidine/uridine monophosphate kinase 2 (CMPK2), 
and the altered levels of H3K27ac was validated in an additional 
cohort of patients with SSc (n=14) and healthy donors (n=5) by 
targeted ChIP-qPCR analysis (figure 2D,E). Most importantly, the 
upregulation of both the histone mark and gene expression was 
similar for all SSc subsets analysed (online supplementary figure 
S2), was not correlated to disease duration (not shown) and was 
also observed in patients with eaSSc (figure 2E). In summary, 
hyperactive promoters were reproducibly associated with genes 
involved in pathways altered in SSc monocytes and previously 
linked to SSc pathogenesis and severity, even before the onset of 
fibrosis.15 16
Genes with altered promoters in ssc monocytes are regulated 
by the sTAT and IrF transcription factor families
The presence of H3K4me3 and H3K27ac near the TSS strongly 
correlates with transcription factor (TF) binding and gene expres-
sion.26 27 Prediction analysis for TF binding sites was performed 
on genomic sequences characterised by altered histone marks 
in SSc. As TF predominantly binds in DNAse-hypersensitive 
sites (DHS)28 the intersection of ChIPseq data with DHS tracks 
specific for CD14+ monocytes was used to conduct the analysis 
(figure 3A).
An enrichment of binding sites for IRF and STAT TF family 
members was found in both hypermethylated and hyperacetylated 
regions in SSc monocytes (figure 3B). Confirming this prediction, 
166 out of the 236 genes whose expression is correlated with 
increased histone mark deposition are reported to have a STAT 
or IRF binding site at their genomic locus (figure 3C). Ingenuity 
pathway analysis provided further evidence that the most rele-
vant upstream TFs driving the expression of upregulated genes 
in SSc monocytes are STAT and IRF family members (figure 3D). 
Consistently, 82% of the genes associated with increased histone 
marks significantly correlated with the expression of at least one 
IRF or STAT gene (online supplementary table S1) suggesting that 
these TFs can underlie the altered activation of gene expression 
observed in SSc monocytes, in association with variations in chro-
matin marks.
The significant correlation of MX1 expression with STAT1 and 
STAT2 identified in the sequencing was replicated by qPCR anal-
ysis in a validation cohort comprising 79 patients with SSc and 19 
HCs (figure 3E). A similar result was found for CMPK2 (online 
supplementary figure S3A). Most importantly, both STAT1 and 
STAT2 were enriched on the promoter of MX1 and CMPK2 in 
a proof-of-concept experiment where monocytes were stimulated 
with IFNα (figure 3F; online supplementary figure S3B). STAT1/2 
recruitment was paralleled by a similar level of induction in MX1/
CMPK2 expression (online supplementary figure S3C) demon-
strating the capability of STAT1 and STAT2 in regulating these 
IFN-responsive genes.
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Figure 1 H3K4me3 and H3K27ac marks are altered in monocytes of patients with SSc in genomic locations important for the regulation of gene 
expression. (A) The abundance of H3K4me3 and H3K27ac was quantified by means of ChIPseq at the genome-wide level using monoclonal antibodies 
recognising these specific histone modifications. The number (and percentage, %) of differentially expressed peaks (p<0.05) in each SSc group or 
between all SSc considered together versus healthy controls (HC) was identified as described in the Methods and materials section and represented 
by Venn diagrams. Upregulated (UP) and downregulated (DOWN) genes are represented in distinct groups. (B) Differentially expressed H3K4me3 
and H3K27ac peaks were intersected with regulatory elements annotated by ENCODE. Bar graphs indicate the percentage of peaks overlapping with 
previously annotated regulatory regions. (C) Genes were categorised into seven ranks according to the fold change in mRNA expression, from log2FC 
higher than 1 to lower than −1. The total amount of H3K4me3/H3K27ac peaks identified (all) or only those significantly higher (up) or lower (down) 
in patients with SSc compared with healthy donors was associated to the aforementioned categories of genes for all genes having their TSS within 
20 kbp from the peak. The ratio of upregulated genes over the downregulated genes for each group of peaks was normalised for the ratio observed 
in the (all) group and reported on the top of each bar. The χ2 test was used to assess significant differences in the distribution of up/downregulated 
genes when associated to differentially abundant peaks as compared with the total distribution (all). FC, fold change. **P<0.01; ***P<0.001. dcSSc, 
diffuse cutaneous SSc; FC, fold change; ns, not significant; SSc, systemic sclerosis; TF, transcription factor; TSS, transcription start site.
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Figure 2 Altered H3K4me3 and H3K27ac levels correlate with gene expression in SSc monocytes. (A) Venn diagram indicating the amount (and 
percentage, %) of genes whose expression is directly and significantly correlated to changes in the level of H3K27ac or H3K4me3 within 20 kbp of 
their transcription start site (TSS) (p<0.05). Only genes associated to peaks that were significantly altered (either ‘up’ or ‘down’) in patients with 
SSc versus healthy donors were considered. (B) Pathways significantly enriched on the combined list of genes correlated to significantly upregulated 
H3K27ac and/or H3K4me3 peaks within 20 kbp from their TSS. Pathways were grouped in those IFN related (black), leading to immune cell 
activation (white) and implicated in response to infection (grey). Bar graph represents the number of genes in each pathway, while dots indicate the 
corresponding enrichment p value after controlling for the false discovery rate (FDR) using the Benjamini–Hochberg (B&H) procedure. (C) Correlation 
of the expression of myxoma resistance protein 1 (MX1) and cytidine/uridine monophosphate kinase 2 (CMPK2) with the level of H3K27ac within 
20 kbp from the TSS in the discovery cohort. (D) RT-qPCR quantification of MX1 and CMPK2 expression in the ChIP-qPCR validation cohort. (E) ChIP-
qPCR analysis of H3K27ac at the promoter of MX1 and CMPK2 in the ChIP-qPCR validation cohort. Detection of H3k27ac at the promoter of prolactin 
(PRL) was used as a negative control. Data are expressed as enrichment percentage over input DNA, horizontal bars represent means. eSSc, early SSc; 
FC, fold change; HC, healthy controls; IFN, interferon; ncSSc, non-cutaneous SSc; SSc, systemic sclerosis.
Histone-modifying enzymes and bromodomain-containing 
proteins are associated with aberrant gene expression in 
patients with ssc
To further unravel those factors leading to altered histone marks 
and thus influencing gene expression in SSc monocytes, we used 
RNAseq data to retrieve the expression of 164 enzymes involved 
in the deposition of methylation and acetylation marks, such as 
histone methyltransferases, demethylases, histone acetyltrans-
ferase or deacetylases and acetylation readers such as bromo-
domain-containing proteins (online supplementary table S2).
The expression of 12 histone-modifying enzymes was altered 
in SSc monocytes compared with HC monocytes (online supple-
mentary figure S4A), including a signature possibly leading to 
an overall increased acetylation, namely the decreased expres-
sion of chromobox 4 (CBX4), Msx2-interacting protein (SPEN) 
and suppressor of variegation 3-9 homologue 1 (SUV39H1) that 
can result in a reduced histone deacetylation activity,29–31 and 
the increased expression of inhibitor of growth family member 
4 (ING4) that can enhance H3K27ac deposition32 (figure 4A). 
Importantly, the altered expression of these genes was also 
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Figure 3 H3K4me3 and H3K27ac peaks associated with upregulated genes overlap binding sites for transcription factors of the IRF and STAT 
family and overlap with their expression. (A) Example of overlap of the tracks for H3K4me3, H3K27ac as detected by ChIPseq and the DNAse 
hypersensitive sites (DHS) signal from the ENCODE/OpenChrom database (GSE32970). (B) List of the top 10 transcription factor binding sites enriched 
under DHS overlapping with H3K27ac or H3K4me3 peaks significantly altered in patients with SSc, versus a set of 10% randomly selected peaks 
from the DHS data set. The adjusted p values were obtained using Bonferroni correction. (C) Number of H3K27ac and H3K4me3 peaks correlated to 
upregulated genes in SSc monocytes that contain a STAT or IRF binding site annotated in the ENSEMBL regulatory build 76.56 STAT1 and STAT2 are 
also represented individually. (D) Upstream regulator analysis performed with ingenuity pathway analysis. Top 10 transcription factors predicted to 
regulate the genes whose expression correlated to altered levels of H3K4me3 and H3K27ac (p<0.1) within 50 kb from their transcription start site 
(TSS). (E) Correlation between the expression of MX1 with STAT1 and STAT2 in the discovery cohort based on RNAseq data (left panels) and the 
validation cohort according to qPCR analysis (right panels). (F) ChIP-qPCR quantification of STAT1 (top) and STAT2 (bottom) bound at the promoter of 
MX1 in monocytes cultured for 2 hours either with or without IFNα. Analysis of STAT binding at the promoter of PRL was used as a negative control. 
Data shown as a percentage of the input DNA, assayed in triplicate, error bars indicate SEM. FC, fold change; HC, healthy controls; IFN, interferon; 
MX1, myxoma resistance protein 1; PRL, prolactin; SSc, systemic sclerosis.
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Figure 4 Aberrant histone acetylation deposition and reading may be implicated in the altered transcriptome of SSc monocytes. (A) Expression 
levels of chromobox 4 (CBX4), Msx2-interacting protein (SPEN), suppressor of variegation 3-9 homologue 1 (SUV39H1) and inhibitor of growth 
family member 4 (ING4) quantified in the discovery cohort by RNAseq. (B) Induction of MX1 and CMPK2 gene expression upon stimulation of healthy 
monocytes with interferon-α (IFNα) for 2 hours in the absence or presence of JQ1, as quantified by means of qPCR analysis. CMPK2, cytidine/uridine 
monophosphate kinase 2; FC, fold change; HC, healthy controls; MX1, myxoma resistance protein 1; ncSSc, non-cutaneous SSc; SSc, systemic sclerosis.
detected in patients with SSc not yet presenting with skin fibrosis 
(figure 4A). Interestingly, treatment of healthy monocytes with 
IFNα led to a similar regulation pattern for the majority of 
histone-modifying enzymes altered in SSc monocytes (8 out of 12, 
online supplementary figure S4B,C), while after stimulation with 
ligands for TLR7 (3 M-055) or TLR8 (VTX-2337) this pattern 
was not observed (online supplementary figure S5). Addition-
ally, IFNα induced the deposition of acetylation on the promoter 
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of MX1 and CMPK2, two IFN-dependent genes found to be 
associated with increased acetylation in SSc monocytes (online 
supplementary figure S6). Using JQ1, a potent inhibitor of the 
BET family of bromodomain proteins that work as acetylation 
readers, we could inhibit the induction of both acetylation and 
expression of MX1 and CMPK2, validating the role of acetyla-
tion in the expression of genes found to be altered in SSc mono-
cytes (figure 4B). These results suggest that a disrupted control 
of histone acetylation in SSc monocytes may determine, at least 
partially, the variations observed in gene expression, including at 
the early disease stage. Additionally, modulation of acetylation 
reading could restore gene expression back to basal levels.
dIsCussIon
SSc is a complex multifactorial autoimmune disease whose patho-
genesis is suggested to be orchestrated by genetic and epigenetic 
aberrances.20 33 As accumulating studies indicate the therapeutic 
potential of epigenetic targeting, we sought evidence for an 
epigenetic distortion underlying the transcriptome alterations of 
SSc monocytes, including the well-known type I IFN signature. 
This study reports for the first time in the field of SSc research a 
profile of two specific histone modifications at the genome-wide 
level. Combining ChIPseq data with publicly available data from 
ENCODE, we defined the presence of active enhancers and 
promoters, marked respectively by H3K27ac and H3K27ac plus 
H3K4me3, and verified that SSc monocytes are characterised 
by hypoactive and hyperactive regulatory elements. Consistent 
with the knowledge that histone modifications are key epigen-
etic factors in immune cells both in differentiation and activa-
tion processes,34 35 we demonstrated that altered chromatin 
marks, epigenetically imprinting the activation of promoters and 
enhancers, are associated with modified gene expression in SSc 
monocytes.
We demonstrated that, in SSc monocytes, alterations in the 
expression of genes, in particular those involved in pathways 
related to the IFN response and cytokine signalling, are associ-
ated with altered promoter and enhancer activity. Among these, 
two of the most significantly correlated genes were MX1 and 
CMPK2. The expression of MX1 and other IFN-dependent genes 
in the lesional skin of patients with SSc was reported to correlate 
with clinical features, such as the skin thickness,18 and coincides 
with the development of digital ulcers,16 a decreased lung func-
tion15 and a more severe phenotype associated with increased 
mortality.36 The altered expression of IFN-responsive genes is 
evident from the earliest stages of the disease and is suggested 
to contribute to the pathogenesis and progression of SSc.11 12 37 
Consistently, we observed that alterations in histone acetylation 
and methylation associated to IFN-related genes are similar in all 
SSc subsets and are also found in patients with eaSSc, suggesting 
they may contribute to disease onset by initiating or sustaining 
this pathway. As the IFN signature is not limited to monocytes, 
it is possible that the altered deposition of histone modifica-
tions at the promoters of IFN-responsive genes is a common 
feature of multiple cell types in SSc. Considering that increased 
histone acetylation and methylation levels have also been previ-
ously reported in other systemic autoimmune diseases, such as 
systemic lupus erythematosus,38–40 along with the presence of 
IFN signature, aberrant activation of promoters and enhancers 
may be a common occurrence in systemic autoimmunity.
Besides the association with IFN-responsive genes, increased 
H3K4me3 levels were correlated with the expression of inter-
leukin-8 (IL8) receptors CXCR1 and CXCR2 and the C-C 
chemokine receptor type 1 (CCR1) (online supplementary table 
S3). These receptors were directly linked to the transendothe-
lial migration of monocytes41 42 and their arrest to activated 
endothelium.43 These observations, along with the notion that 
monocytes/macrophages infiltrate the SSc skin, suggest that 
the enhanced migratory phenotype of SSc monocytes5 may be 
supported by the altered activity of the promoters of chemo-
kine receptor genes. Considering the role of monocyte infil-
tration as a potential trigger of fibrosis,44 these findings can be 
of utmost importance from the therapeutic perspective. Inter-
estingly, also five members of the activating-type Fc receptors 
for IgG family (FCGR1B, FCGR1C, FCGR2A, FCGR3A and 
FCGR3B) are hypermethylated near their TSS in SSc monocytes 
(online supplementary table S3). Though the role of Fc receptors 
in autoimmune diseases has not been fully elucidated, studies 
suggest that the uptake of immune complexes via Fc receptors 
leads to activation of toll-like receptor 7 or 9 and the production 
of cytokines such as IFN and IL8.45 46 Overall, these observa-
tions suggest that the altered histone acetylation and methylation 
levels observed in SSc monocytes have a broad impact on their 
transcriptome profile, particularly on genes linked to pathways 
known to impact monocyte biology and likely linked to disease 
pathogenesis.
Chromatin alterations are not directly responsible for the 
induced gene expression. The deposition of H3K27ac and 
H3K4me3 leads to chromatin unwinding, increasing acces-
sibility to TFs driving the expression of target genes.25 28 In 
hyperacetylated and hypermethylated regions in SSc, we identi-
fied a strong enrichment of binding sites for various STAT and 
IRF TFs. Additionally, the expression of STAT1 and STAT2 was 
significantly increased in SSc monocytes and their expression 
strongly correlated with genes containing their binding site 
near the TSS (online supplementary table S1), including MX1 
and CMPK2. Furthermore, the binding of STAT1 and STAT2 
to the promoters of MX1 and CMPK2 increased upon stimu-
lation with IFNα. This demonstrated that STATs are, at least 
partially, responsible for the altered expression of these genes in 
SSc monocytes and suggests that this causal relationship may be 
extended to other factors whose binding site is enriched under 
the altered chromatin marks. In line with these findings, the 
presence of IFNα and phosphorylated STAT1 in the affected 
skin of patients with SSc was previously shown47 and GWAS 
identified SSc-risk loci in regions encoding for various STAT 
and IRF TFs.48–52
Considering the importance of H3K27ac and H3K4me3 
chromatin marks in sustaining gene expression, proteins respon-
sible for the deposition and maintenance of these histone 
modifications and their binding partners may entail novel ther-
apeutic targets in SSc. Twelve of such enzymes were differen-
tially expressed in patients with SSc, potentially leading to an 
increased H3K27ac and/or H3K4me3 status, through different 
mechanisms.29–32 A consistent subset of such genes was also 
modulated, in the same direction, upon stimulation of healthy 
monocytes with IFNα. Consistently, IFNα induced the deposi-
tion of H3K27ac at the promoter of genes found altered in SSc 
monocytes. In the light of these results, we can speculate that 
exposure of monocytes to IFNα, possibly released by activated 
plasmacytoid DCs,45 53 represents one of the factors affecting 
chromatin modifiers/readers and H3K27ac deposition in SSc 
monocytes, thus ultimately establishing the type I IFN signature. 
Further investigations should be directed to unravel the patho-
genetic pathways contributing to increased H3K4me3, which we 
did not find to be modulated near the selected genes upon IFNα 
stimulation (not shown). In addition to altered soluble factors, 
as previously demonstrated in healthy condition,54 genetic 
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differences may also underlie the altered epigenetic landscape in 
patients with SSc.
Considering that the deposition of chromatin marks is revers-
ible, targeting histone-modifying enzymes could reprogramme 
the epigenetic imprinting of SSc monocytes and constitute a 
potential therapeutic strategy to revert their activated phenotype 
and block the development of fibrosis. This is particularly inter-
esting considering that these enzymes and the H3K27ac levels 
are already altered in patients before the onset of fibrosis. In a 
proof-of-concept experiment using IFNα-stimulated monocytes 
we demonstrated that interfering with acetylation readers, that 
is, by inhibiting the activation of the transcriptional machinery 
using JQ1, modulates both the acetylation and the expression of 
genes that are also dysregulated in SSc monocytes. The inhibi-
tion of bromodomain proteins with compounds similar to JQ1 
has previously shown clinical efficacy in in vitro and animal 
models for various autoimmune disorders.55
Taken together, as epigenetic targeting of the immune system 
holds great promise for the treatment of immune-mediated 
inflammatory diseases, our data justify further research on the 
role of chromatin modifiers as therapeutic targets in SSc. At the 
early stages of disease onset, such targeting could aim at disease 
interception.
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